Clene Inc. last reported quarterly results on Nov 4, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $56,000 (+273.3% year over year) and diluted EPS of $0.05. It usually reports 35–71 days after a quarter ends. Based on that pattern, the next release is estimated for around Mar 11, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Thursday. Based on last year's release for the same quarter on Mar 12, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 35–71 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 4, 2026
35 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
0
+273.3%
|
4
+144.6%
|
0.05
|
|
Aug 14, 2026
45 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
0
+233.3%
|
-13
-80.9%
|
—
|
|
May 14, 2026
44 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
0
-81.5%
|
-8
-977.4%
|
—
|
|
Mar 12, 2026
71 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
0
-15.4%
|
-9
+31.9%
|
—
|
|
Oct 14, 2025
14 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
0
-82.8%
|
-9
-9.9%
|
—
|
|
Aug 14, 2025
45 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
0
-70.3%
|
-7
-9.3%
|
—
|
|
May 7, 2025
37 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
0
+11.0%
|
-1
+93.2%
|
—
|
|
Nov 13, 2024
44 days after quarter end
|
—
ended Sep 30, 2024
|
—
|
—
|
—
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CLNN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Salt Lake City, UT
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1822791
- Former names
- Chelsea Worldwide Inc. (until Dec 18, 2020)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.